

Josã© Antonio da Silva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3727969/publications.pdf>

Version: 2024-02-01

202
papers

14,353
citations

81434

41
h-index

24511

114
g-index

211
all docs

211
docs citations

211
times ranked

15093
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence on “Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment”. Annals of the Rheumatic Diseases, 2023, 82, e183-e183.	0.5	3
2	Antimalarial treatment and minimizing prednisolone are associated with lower risk of infection in SLE: a 24-month prospective cohort study. Clinical Rheumatology, 2022, 41, 1069-1078.	1.0	5
3	Correspondence on “Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment” by Felson et al. ACR Open Rheumatology, 2022, 4, 271-272.	0.9	1
4	Reexamining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level, and patient global assessment: comment on the article by Felson et al. Arthritis Care and Research, 2022, 74, 501-502.	1.5	0
5	Ultrasound and elastography in the assessment of skin involvement in systemic sclerosis: A systematic literature review focusing on validation and standardization “ WSF Skin Ultrasound Group. Seminars in Arthritis and Rheumatism, 2022, 52, 1519-1524.	1.6	14
6	Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial. American Journal of Clinical Nutrition, 2022, 115, 1311-1321.	2.2	16
7	Prevalence and incidence of iron deficiency in European community-dwelling older adults: an observational analysis of the DO-HEALTH trial. Aging Clinical and Experimental Research, 2022, 34, 2205-2215.	1.4	15
8	The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence. Current Opinion in Rheumatology, 2022, 34, 179-186.	2.0	4
9	Treating-to-target in rheumatology: Theory and practice. Best Practice and Research in Clinical Rheumatology, 2022, 36, 1017-1035.	1.4	12
10	Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort. Rheumatology, 2022, 61, 3309-3316.	0.9	14
11	Human Bone Marrow Mesenchymal Stromal/Stem Cells Regulate the Proinflammatory Response of Monocytes and Myeloid Dendritic Cells from Patients with Rheumatoid Arthritis. Pharmaceuticals, 2022, 14, 404.	2.0	5
12	Combined Vitamin D, Omega-3 Fatty Acids, and a Simple Home Exercise Program May Reduce Cancer Risk Among Active Adults Aged 70 and Older: A Randomized Clinical Trial. Frontiers in Aging, 2022, 3, .	1.2	13
13	Patient Experienced Symptom State in rheumatoid arthritis: sensitivity to change in disease activity and impact. Rheumatology, 2022, 62, 98-107.	0.9	1
14	Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Annals of the Rheumatic Diseases, 2022, 81, 925-936.	0.5	59
15	Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. Osteoporosis International, 2022, 33, 2103-2136.	1.3	33
16	Comment on: “It can’t be zero!” difficulties in completing patient global assessment in rheumatoid arthritis: a mixed methods study: reply. Rheumatology, 2021, 60, e30-e31.	0.9	0
17	2019 EULAR points to consider for the assessment of competences in rheumatology specialty training. Annals of the Rheumatic Diseases, 2021, 80, 65-70.	0.5	12
18	Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients. Annals of the Rheumatic Diseases, 2021, 80, 293-303.	0.5	32

#	ARTICLE	IF	CITATIONS
19	Attainment of the Patient-acceptable Symptom State in 548 patients with rheumatoid arthritis: Influence of demographic factors. <i>Joint Bone Spine</i> , 2021, 88, 105071.	0.8	5
20	DO-HEALTH: Vitamin D3 - Omega-3 - Home exercise - Healthy aging and longevity trial - Design of a multinational clinical trial on healthy aging among European seniors. <i>Contemporary Clinical Trials</i> , 2021, 100, 106124.	0.8	28
21	Happiness, quality of life and their determinants among people with systemic sclerosis: a structural equation modelling approach. <i>Rheumatology</i> , 2021, 60, 4717-4727.	0.9	8
22	Barriers and potential solutions in the recruitment and retention of older patients in clinical trials—lessons learned from six large multicentre randomized controlled trials. <i>Age and Ageing</i> , 2021, 50, 1988-1996.	0.7	17
23	Patients' and rheumatologists' perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis—an international survey within the GLORIA study. <i>Rheumatology</i> , 2021, 60, 3334-3342.	0.9	13
24	Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients. <i>RMD Open</i> , 2021, 7, e001539.	1.8	10
25	Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study. <i>Rheumatology</i> , 2021, 60, 5134-5141.	0.9	18
26	SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study. <i>Lancet Rheumatology</i> , The, 2021, 3, e481-e488.	2.2	25
27	POS0055...SARS-COV-2 OUTBREAK IN AUTOIMMUNE DISEASES: THE EURO-COVIMID STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 233-234.	0.5	1
28	EULAR portfolio for Rheumatology training: a EULAR School of Rheumatology initiative. <i>RMD Open</i> , 2021, 7, e001684.	1.8	2
29	Definition of Treatment Targets in Rheumatoid Arthritis: Is It Time for Reappraisal?. <i>Journal of Rheumatology</i> , 2021, 48, 1763-1766.	1.0	8
30	Frequência de síndrome metabólica em estudantes de uma universidade pública brasileira. <i>Research, Society and Development</i> , 2021, 10, e37101219802.	0.0	0
31	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1108-1112.	1.6	8
32	High patient global assessment scores in patients with rheumatoid arthritis otherwise in remission do not reflect subclinical inflammation. <i>Joint Bone Spine</i> , 2021, 88, 105242.	0.8	17
33	Fibromyalgia position paper. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 130, 186-193.	0.4	1
34	Diagnostic and therapeutic care pathway for fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 130, 120-127.	0.4	0
35	Dual-target strategy: fostering person-centered care in rheumatology. <i>Acta Reumatológica Portuguesa</i> , 2021, 46, 99-102.	0.2	1
36	Diagnostic and therapeutic care pathway for fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 120-127.	0.4	4

#	ARTICLE	IF	CITATIONS
37	Editorial: Osteoporosis in Rheumatic Diseases, What's New?. <i>Frontiers in Medicine</i> , 2021, 8, 808345.	1.2	2
38	Fibromyalgia position paper. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 186-193.	0.4	29
39	Topical NSAIDs for chronic musculoskeletal pain in adults. <i>The Cochrane Library</i> , 2020, 2020, CD007400.	1.5	168
40	Association of 17 Definitions of Remission with Functional Status in a Large Clinical Practice Cohort of Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 20-27.	1.0	3
41	Immunomodulatory effect of human bone marrow-derived mesenchymal stromal/stem cells on peripheral blood T cells from rheumatoid arthritis patients. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2020, 14, 16-28.	1.3	30
42	"It can't be zero!" Difficulties in completing patient global assessment in rheumatoid arthritis: a mixed methods study. <i>Rheumatology</i> , 2020, 59, 1137-1147.	0.9	19
43	Shared decision-making in people with chronic disease: Integrating the biological, social and lived experiences is a key responsibility of nurses. <i>Musculoskeletal Care</i> , 2020, 18, 84-91.	0.6	8
44	Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1855.	3.8	180
45	The Patient Experienced Symptom State (PESS): a patient-reported global outcome measure that may better reflect disease remission status. <i>Rheumatology</i> , 2020, 59, 3458-3467.	0.9	6
46	How much of skin improvement over time in systemic sclerosis is due to normal ageing? A prospective study with shear-wave elastography. <i>Arthritis Research and Therapy</i> , 2020, 22, 50.	1.6	13
47	Prevalence of vitamin D deficiency and its predictors in the Portuguese population: a nationwide population-based study. <i>Archives of Osteoporosis</i> , 2020, 15, 36.	1.0	22
48	Progress towards improved non-pharmacological management of fibromyalgia. <i>Joint Bone Spine</i> , 2020, 87, 377-379.	0.8	11
49	Recent Patents on Impact of Lipopeptide on the Biofilm Formation onto Titanium and Stainless Steel Surfaces. <i>Recent Patents on Biotechnology</i> , 2020, 14, 49-62.	0.4	10
50	Patient global assessment and radiographic progression in early arthritis: 3-year results from the ESPOIR cohort. <i>Arthritis Care and Research</i> , 2020, 73, 1300-1305.	1.5	9
51	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.5	1,860
52	The patient global assessment in RA precludes the majority of patients otherwise in remission to reach this status in clinical practice. Should we continue to ignore this?. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 583-585.	1.6	18
53	THU0586...ESTABLISHING THE KEY COMPONENTS OF A EULAR PORTFOLIO FOR TRAINING IN RHEUMATOLOGY: A EULAR SCHOOL OF RHEUMATOLOGY INITIATIVE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 535.1-535.	0.5	1
54	AB0179...BEYOND DISEASE ACTIVITY, PAIN, "TIME" AND "TIMING" ACCOUNT FOR DISABILITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM A REAL-LIFE COHORT. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1389-1389.	0.5	0

#	ARTICLE	IF	CITATIONS
55	SAT0184â€¦...MAINTENANCE THERAPY WITH AZATHIOPRINE ASSOCIATED WITH HIGHER RISK OF FLARE IN PROLIFERATIVE LUPUS NEPHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1033-1034.	0.5	0
56	Educational needs in people with ankylosing spondylitis and psoriatic arthritis: a cross-sectional study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 282-288.	0.4	1
57	Depression, disability and sleep disturbance are the main explanatory factors of fatigue in rheumatoid arthritis: a path analysis model. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 314-321.	0.4	7
58	Ultrasonography for the Assessment of Skin in Systemic Sclerosis: A Systematic Review. <i>Arthritis Care and Research</i> , 2019, 71, 563-574.	1.5	39
59	Reply. <i>Arthritis Care and Research</i> , 2019, 71, 695-696.	1.5	1
60	Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e109-e109.	0.5	35
61	The impact of fatigue in rheumatoid arthritis and the challenges of its assessment. <i>Rheumatology</i> , 2019, 58, v3-v9.	0.9	29
62	Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 340-341.	0.6	1
63	205â€œFrom zero to ten: difficulties in completing patient global assessment in rheumatoid arthritis: a mixed-methods study. <i>Rheumatology</i> , 2019, 58, .	0.9	0
64	Impact of Patient's Global Assessment on Achieving Remission in Patients With Rheumatoid Arthritis: A Multinational Study Using the METEOR Database. <i>Arthritis Care and Research</i> , 2019, 71, 1317-1325.	1.5	41
65	FRIO123â€¦...BIOLOGICAL THERAPIES SURVIVAL IN RHEUMATOID ARTHRITIS PATIENTSIN CLINICAL PRACTICE: RESULTS FROM THE METEOR REGISTRY. , 2019, , .		0
66	Effectiveness of non-pharmacological and non-surgical interventions for rheumatoid arthritis: an umbrella review. <i>JB I Database of Systematic Reviews and Implementation Reports</i> , 2019, 17, 1494-1531.	1.7	28
67	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. <i>Journal of Clinical Medicine</i> , 2019, 8, 2013.	1.0	118
68	Effectiveness of non-pharmacological and non-surgical interventions on the impact of rheumatoid arthritis. <i>JB I Database of Systematic Reviews and Implementation Reports</i> , 2019, 17, 22-27.	1.7	4
69	Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 365-371.	0.5	88
70	The impact of transducer frequency in ultrasound evaluation of subclinical skin involvement in limited cutaneous systemic sclerosis patients. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 147-148.	0.4	2
71	Validation of Rheumatoid Arthritis Quality of Life (RAQoL) Questionnaire into Portuguese Language. <i>Acta ReumatolÃ³gica Portuguesa</i> , 2019, 44, 65-70.	0.2	0
72	Glucocorticoids Are Always Under Suspicion â€” Is the Perception of Their Risks Unbiased?. <i>Journal of Rheumatology</i> , 2018, 45, 293-296.	1.0	6

#	ARTICLE	IF	CITATIONS
73	Influence of the different "patient global assessment" formulations on disease activity score by different indices in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 1963-1969.	1.0	14
74	Just a painful swelling of the ankles?. <i>BMJ: British Medical Journal</i> , 2018, 360, k436.	2.4	0
75	Is current smoking status and its relationship to anti-cyclic citrullinated peptide antibodies a predictor of worse response to biological therapies in rheumatoid arthritis patients?. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 360-363.	0.6	7
76	Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modelling approach. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212934.	0.5	19
77	Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis. <i>Lupus</i> , 2018, 27, 1358-1362.	0.8	27
78	The controversy of using PGA to define remission in RA. <i>Nature Reviews Rheumatology</i> , 2018, 14, 245-245.	3.5	5
79	Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change. <i>Arthritis Care and Research</i> , 2018, 70, 369-378.	1.5	84
80	Preventing progression from arthralgia to arthritis: targeting the right patients. <i>Nature Reviews Rheumatology</i> , 2018, 14, 32-41.	3.5	91
81	Increased frequencies of circulating CXCL10-, CXCL8- and CCL4-producing monocytes and Siglec-3-expressing myeloid dendritic cells in systemic sclerosis patients. <i>Inflammation Research</i> , 2018, 67, 169-177.	1.6	28
82	The leopard woman: a subacute and rare presentation. <i>Rheumatology</i> , 2018, 57, 428-428.	0.9	0
83	OPO160-HPR...Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modelling approach. , 2018, , .		0
84	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. <i>Arthritis and Rheumatology</i> , 2018, 70, 1829-1834.	2.9	15
85	The Portuguese Rheumatoid Arthritis Impact of Disease (RAID) score and its measurement equivalence in three countries: validation study using Rasch Models. <i>Quality of Life Research</i> , 2018, 27, 2909-2921.	1.5	8
86	Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations. <i>Frontiers in Medicine</i> , 2018, 5, 40.	1.2	26
87	Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 67.	0.7	32
88	The many faces of IgG4-related disease: report of a case with inaugural recurrent aortic aneurism ruptures and literature review. <i>Rheumatology International</i> , 2018, 38, 1565-1570.	1.5	5
89	Timing of onset affects arthritis presentation pattern in antisynthetase syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 44-49.	0.4	30
90	The impact of patient global assessment in the definition of remission as a predictor of long-term radiographic damage in patients with rheumatoid arthritis: protocol for an individual patient data meta-analysis. <i>Acta Reumatolgica Portuguesa</i> , 2018, 43, 52-60.	0.2	5

#	ARTICLE	IF	CITATIONS
91	Systemic oxalosis in hyperoxaluria type 1. <i>Rheumatology</i> , 2017, 56, kew380.	0.9	0
92	EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 802-810.	0.5	111
93	Invalidation in Patients with Rheumatic Diseases: Clinical and Psychological Framework. <i>Journal of Rheumatology</i> , 2017, 44, 512-518.	1.0	31
94	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.5	3,366
95	Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. <i>Rheumatology</i> , 2017, 56, 1573-1578.	0.9	71
96	Do we need bone mineral density to estimate osteoporotic fracture risk? A 10-year prospective multicentre validation study. <i>RMD Open</i> , 2017, 3, e000509.	1.8	18
97	Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1889-1893.	1.0	15
98	Chronic widespread pain and increased mortality: biopsychosocial interconnections. <i>Annals of the Rheumatic Diseases</i> , 2017, 77, annrheumdis-2017-211893.	0.5	9
99	OP0144-HPR can't be zero: a qualitative study of patients' perspective on patient global assessment in rheumatoid arthritis. , 2017, , .		2
100	Predictors of response to TNF blockers in patients with polyarticular psoriatic arthritis. <i>Acta Reumatolgica Portuguesa</i> , 2017, 42, 55-65.	0.2	4
101	Can health care providers recognise a fibromyalgia personality?. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 105, 43-49.	0.4	1
102	General Practitioners and Rheumatologists: new bridges for a successful cooperation. <i>Acta Reumatolgica Portuguesa</i> , 2017, 42, 6-7.	0.2	1
103	The Portuguese Society of Rheumatology position paper on the use of biosimilars - 2017 update. <i>Acta Reumatolgica Portuguesa</i> , 2017, 42, 219-228.	0.2	4
104	Unilateral calf hypertrophy and radiculopathy: an unusual association. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217744.	0.2	3
105	Exercise echocardiography for the assessment of pulmonary hypertension in systemic sclerosis: a systematic review. <i>Arthritis Research and Therapy</i> , 2016, 18, 153.	1.6	12
106	Subset-specific alterations in frequencies and functional signatures of T cells in systemic sclerosis patients. <i>Inflammation Research</i> , 2016, 65, 985-994.	1.6	15
107	AB1069The Educational Needs of People with Spondyloarthropathies (AS and PSA): A Cross-Sectional Study: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1267.2-1267.	0.5	0
108	Rheumatology training experience across Europe: analysis of core competences. <i>Arthritis Research and Therapy</i> , 2016, 18, 213.	1.6	19

#	ARTICLE	IF	CITATIONS
109	CD38, CD81 and BAFFR combined expression by transitional B cells distinguishes active from inactive systemic lupus erythematosus. <i>Clinical and Experimental Medicine</i> , 2016, 16, 227-232.	1.9	16
110	Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX® in Portugal. <i>Calcified Tissue International</i> , 2016, 99, 131-141.	1.5	25
111	The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 795-810.	0.5	780
112	The prevalence of severe fatigue in rheumatic diseases: an international study. <i>Clinical Rheumatology</i> , 2016, 35, 409-415.	1.0	147
113	A preliminary study using virtual touch imaging and quantification for the assessment of skin stiffness in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 137-141.	0.4	14
114	Multidisciplinary Portuguese recommendations on DXA request and indication to treat in the prevention of fragility fractures. <i>Acta Reumatológica Portuguesa</i> , 2016, 41, 305-321.	0.2	1
115	Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 349-354.	0.5	7
116	The importance of heat against antinutritional factors from <i>Chenopodium quinoa</i> seeds. <i>Food Science and Technology</i> , 2015, 35, 74-82.	0.8	7
117	TRAF1/C5 but Not PTPRC Variants Are Potential Predictors of Rheumatoid Arthritis Response to Anti-Tumor Necrosis Factor Therapy. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	15
118	Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. <i>BioMed Research International</i> , 2015, 2015, 1-13.	0.9	19
119	Kyphoscoliosis: looking beyond the spine. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014209096-bcr2014209096.	0.2	0
120	Sera from patients with active systemic lupus erythematosus patients enhance the toll-like receptor 4 response in monocyte subsets. <i>Journal of Inflammation</i> , 2015, 12, 38.	1.5	8
121	Outcome Measures in Polymyalgia Rheumatica. A Systematic Review. <i>Journal of Rheumatology</i> , 2015, 42, 2503-2511.	1.0	14
122	Characterization of damage in Portuguese lupus patients: analysis of a national lupus registry. <i>Lupus</i> , 2015, 24, 256-262.	0.8	26
123	Differences and similarities in rheumatology specialty training programmes across European countries. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1183-1187.	0.5	18
124	The burden of osteoporotic hip fractures in Portugal: costs, health related quality of life and mortality. <i>Osteoporosis International</i> , 2015, 26, 2623-2630.	1.3	54
125	Operational Definition of Active and Healthy Aging (AHA): The European Innovation Partnership (EIP) on AHA Reference Site Questionnaire: Montpellier October 2014, Lisbon July 2, 2015. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 1020-1026.	1.2	33
126	The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1958-1967.	0.5	128

#	ARTICLE	IF	CITATIONS
127	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015, 102, 19-24.	1.1	13
128	Quality indicators in rheumatoid arthritis: results from the METEOR database. <i>Rheumatology</i> , 2015, 54, 1630-1639.	0.9	23
129	CD8+ T Cell Profiles in Patients With Rheumatoid Arthritis and Their Relationship to Disease Activity. <i>Arthritis and Rheumatology</i> , 2015, 67, 363-371.	2.9	67
130	Safety of Glucocorticoids in Rheumatoid Arthritis: Evidence from Recent Clinical Trials. <i>NeuroImmunoModulation</i> , 2015, 22, 57-65.	0.9	18
131	DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt. <i>Rheumatology</i> , 2015, 54, 286-291.	0.9	22
132	EpiReumaPt- the study of rheumatic and musculoskeletal diseases in Portugal: a detailed view of the methodology. <i>Acta Reumatológica Portuguesa</i> , 2015, 40, 110-24.	0.2	26
133	Milwaukee shoulder (and knee) syndrome. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013202183-bcr2013202183.	0.2	8
134	Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: Outcomes of Importance for Patients with PMR. <i>Journal of Rheumatology</i> , 2014, 41, 819-823.	1.0	28
135	Safety of low to medium dose glucocorticoid treatment in rheumatoid arthritis: myths and reality over the years. <i>Annals of the New York Academy of Sciences</i> , 2014, 1318, 41-49.	1.8	26
136	Nailfold capillary abnormalities in erectile dysfunction of systemic sclerosis: a EUSTAR group analysis. <i>Rheumatology</i> , 2014, 53, 639-643.	0.9	8
137	Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study. <i>Rheumatology</i> , 2014, 53, 85-89.	0.9	45
138	Measurement invariance of the Illness Invalidation Inventory (3*) across language, rheumatic disease and gender. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 551-556.	0.5	19
139	Coexisting primary Sjögren's syndrome and sarcoidosis: coincidence, mutually exclusive conditions or syndrome?. <i>Rheumatology International</i> , 2014, 34, 1619-1622.	1.5	16
140	THU0593-HPR...Severe Fatigue is Highly Prevalent in ALL Rheumatic Diseases: an International Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1197.3-1198.	0.5	0
141	Exercise-induced Pulmonary Hypertension in Scleroderma Patients: A Common Finding but with Elusive Pathophysiology. <i>Echocardiography</i> , 2013, 30, 378-384.	0.3	10
142	A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF agent?. <i>Clinical Rheumatology</i> , 2013, 32, 1819-1822.	1.0	20
143	EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1125-1135.	0.5	1,033
144	EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1905-1913.	0.5	220

#	ARTICLE	IF	CITATIONS
145	Assessment of cardiovascular risk in rheumatoid arthritis patients. <i>European Journal of Internal Medicine</i> , 2013, 24, e135-e136.	1.0	0
146	Distribution and functional plasticity of peripheral blood Th(c)17 and Th(c)1 in rheumatoid arthritis. <i>Rheumatology International</i> , 2013, 33, 2093-2099.	1.5	17
147	Potential roles for CD8+ T cells in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2013, 12, 401-409.	2.5	78
148	NK cells dysfunction in systemic lupus erythematosus: relation to disease activity. <i>Clinical Rheumatology</i> , 2013, 32, 805-813.	1.0	69
149	Preface. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 121.	1.4	0
150	Developing a professional approach to work-based assessments in rheumatology. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 123-136.	1.4	5
151	A10.5â€¦Comparative Effectiveness of Biological Therapies in Rheumatoid Arthritis is Influenced by Response Measures and Disease Activity State. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A73.1-A73.	0.5	0
152	FRI0096â€¦Haq baseline values in an international registry of ra patients during the era of biologic therapies: the 2013 meteor database.. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A402.1-A402.	0.5	0
153	A FRAX model for the estimation of osteoporotic fracture probability in Portugal. <i>Acta ReumatolÃ³gica Portuguesa</i> , 2013, 38, 104-12.	0.2	5
154	Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. <i>Rheumatology</i> , 2012, 51, 2020-2026.	0.9	78
155	Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group. <i>Arthritis Research and Therapy</i> , 2012, 14, R37.	1.6	41
156	Functional characterization of peripheral blood dendritic cells and monocytes in systemic lupus erythematosus. <i>Rheumatology International</i> , 2012, 32, 863-869.	1.5	46
157	Th17 cells in systemic lupus erythematosus share functional features with Th17 cells from normal bone marrow and peripheral tissues. <i>Clinical Rheumatology</i> , 2012, 31, 483-491.	1.0	9
158	Clarifications needed, please. <i>BMJ: British Medical Journal</i> , 2011, 342, d2602-d2602.	2.4	2
159	European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 722-726.	0.5	208
160	Impact of impaired morning function on the lives and well-being of patients with rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2011, 40, 6-11.	0.6	44
161	Rheumatology education in Europe: results of a survey of young rheumatologists. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, 843-5.	0.4	16
162	Selecting men for bone densitometry: performance of osteoporosis risk assessment tools in Portuguese men. <i>Osteoporosis International</i> , 2010, 21, 977-983.	1.3	15

#	ARTICLE	IF	CITATIONS
163	Frequency and functional activity of Th17, Tc17 and other T-cell subsets in Systemic Lupus Erythematosus. Cellular Immunology, 2010, 264, 97-103.	1.4	82
164	Prediction of Vertebral Fractures Is Specific for Gender and Site of Bone Mineral Density Measurement. Journal of Rheumatology, 2010, 37, 149-154.	1.0	6
165	Applying science in practice: the optimization of biological therapy in rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, 220.	1.6	14
166	Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Annals of the Rheumatic Diseases, 2010, 69, 1015-1021.	0.5	117
167	Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Annals of the Rheumatic Diseases, 2010, 69, 1913-1919.	0.5	159
168	Patients- and physicians- priorities for improvement. The case of rheumatic diseases. Acta Reumatológica Portuguesa, 2010, 35, 192-9.	0.2	10
169	Competencies in rheumatology: a European framework. Best Practice and Research in Clinical Rheumatology, 2009, 23, 145-160.	1.4	8
170	Preface. Best Practice and Research in Clinical Rheumatology, 2009, 23, 125.	1.4	0
171	Influência do perfil lipídico em placas ateroscleróticas coronarianas moderadas: análise com ultrassom intracoronariano. Revista Brasileira De Cardiologia Invasiva, 2009, 17, 88-93.	0.1	0
172	Topical diclofenac and its role in pain and inflammation: an evidence-based review. Current Medical Research and Opinion, 2008, 24, 925-950.	0.9	93
173	Chapter 20 Hormonal Modulation of Autoimmune Diseases: Glucocorticoids. Handbook of Systemic Autoimmune Diseases, 2008, 9, 229-240.	0.1	0
174	EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Annals of the Rheumatic Diseases, 2008, 67, 536-541.	0.5	639
175	A questionnaire for listening to students' voices in the assessment of teaching quality in a classical medical school. Assessment and Evaluation in Higher Education, 2008, 33, 445-453.	3.9	2
176	UEMS charter on the training of rheumatologists in Europe. Annals of the Rheumatic Diseases, 2008, 67, 555-558.	0.5	11
177	Performance of decision algorithms for the identification of low bone mineral density in Portuguese postmenopausal women. Acta Reumatológica Portuguesa, 2008, 33, 314-28.	0.2	4
178	EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Annals of the Rheumatic Diseases, 2007, 66, 1560-1567.	0.5	325
179	Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Annals of the Rheumatic Diseases, 2006, 65, 285-293.	0.5	402
180	Effects of Testosterone, 17beta-Estradiol, and Downstream Estrogens on Cytokine Secretion from Human Leukocytes in the Presence and Absence of Cortisol. Annals of the New York Academy of Sciences, 2006, 1069, 168-182.	1.8	56

#	ARTICLE	IF	CITATIONS
181	Revisiting the Toxicity of Low-Dose Glucocorticoids: Risks and Fears. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 275-288.	1.8	19
182	Soft tissue injections. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 503-527.	1.4	16
183	Developments in Glucocorticoid Therapy. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 1-17.	0.8	34
184	The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2005, 34, 14-21.	0.6	107
185	Cervical complications of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2004, 64, 355-358.	0.5	15
186	EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1172-1176.	0.5	183
187	Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 718-722.	0.5	395
188	Differential Male and Female Adrenal Cortical Steroid Hormone and Cortisol Responses to Interleukin-6 in Humans. <i>Annals of the New York Academy of Sciences</i> , 2002, 966, 68-72.	1.8	18
189	Relationships between Glucocorticoids and Gonadal Steroids in Rheumatoid Arthritis. <i>Annals of the New York Academy of Sciences</i> , 2002, 966, 158-165.	1.8	8
190	Destruction of articular cartilage by alpha2 macroglobulin elastase complexes: role in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 109-113.	0.5	31
191	Sex Hormones and Glucocorticoids: Interactions with the Immune System. <i>Annals of the New York Academy of Sciences</i> , 1999, 876, 102-118.	1.8	234
192	Gender Differences in Adrenal and Gonadal Responses to Inflammatory Aggression. <i>Annals of the New York Academy of Sciences</i> , 1999, 876, 148-151.	1.8	7
193	Perturbations of hypothalamic-pituitary-gonadal (HPG) axis and adrenal androgen (AA) functions in rheumatoid arthritis. <i>Bailliere's Clinical Rheumatology</i> , 1996, 10, 295-332.	1.0	50
194	A RANDOMIZED TRIAL OF TESTOSTERONE THERAPY IN MALES WITH RHEUMATOID ARTHRITIS. <i>Rheumatology</i> , 1996, 35, 568-573.	0.9	81
195	Sex steroids affect glucocorticoid response to chronic inflammation and to interleukin-1. <i>Journal of Endocrinology</i> , 1993, 136, 389-397.	1.2	56
196	Protective effect of androgens against inflammation induced cartilage degradation in male rodents. <i>Annals of the Rheumatic Diseases</i> , 1993, 52, 285-291.	0.5	25
197	Pregnancy and Rheumatoid Arthritis: An Overview. <i>American Journal of Reproductive Immunology</i> , 1992, 28, 222-225.	1.2	26
198	The role of pregnancy in the course and aetiology of rheumatoid arthritis. <i>Clinical Rheumatology</i> , 1992, 11, 189-194.	1.0	165

#	ARTICLE	IF	CITATIONS
199	The effects of gender and sex hormones on outcome in rheumatoid arthritis. Bailliere's Clinical Rheumatology, 1992, 6, 193-219.	1.0	77
200	Heat shock proteins: the missing link between hormonal and reproductive factors and rheumatoid arthritis?. Annals of the Rheumatic Diseases, 1991, 50, 735-739.	0.5	10
201	JOINT SPACE IN RADIOLOGICALLY NORMAL KNEES. Rheumatology, 1991, 30, 426-428.	0.9	38
202	Predictors of hospitalization in patients with systemic lupus erythematosus: a 10-year cohort study. Clinical Rheumatology, 0, , .	1.0	3